繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Coya Therapeutics宣布发表文章,证明与对照组相比,COYA 302增加了ALS患者的三种生物标志物

2026-04-09 20:04

  • The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparison. Levels of 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL) at diagnosis were significantly correlated with length of survival in patients with ALS. In a previously reported Investigator Initiated Trial that studied the combination of subcutaneous low-dose interleukin 2 (LD IL-2) and CTLA-4 Ig, these biomarkers of survival were reduced from baseline

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。